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Refractory hypotension with end-organ hypoperfusion and
failure is an ominous feature of shock. Distributive shock is
caused by severe infections (septic shock) or severe systemic
allergic reactions (anaphylactic shock). In 1986, it was
concluded that nitric oxide (NO) is the endothelium-derived
relaxing factor that had been discovered 6 years earlier. Since
then, NO has been shown to be important for the
physiological and pathological control of vascular tone.
Nevertheless, although inhibition of NO synthesis restores
blood pressure, NO synthase (NOS) inhibition cannot
improve outcome, on the contrary. This implies that NO acts
as a double-edged sword during septic shock. Consequently,
the focus has shifted towards selective inducible NOS (iNOS)
inhibitors. The contribution of NO to anaphylactic shock
seems to be more straightforward, as NOS inhibition
abrogates shock in conscious mice. Surprisingly, however,
this shock-inducing NO is not produced by the inducible
iNOS, but by the so-called constitutive enzyme endothelial
NOS. This review summarizes the contribution of NO to septic
and anaphylactic shock. Although NOS inhibition may be
promising for the treatment of anaphylactic shock, the failure
of a phase III trial indicates that other approaches are
required for the successful treatment of septic shock.
Amongst these, high hopes are set for selective iNOS
inhibitors. But it might also be necessary to shift gears and
focus on downstream cardiovascular targets of NO or on
other vasodilating phenomena.
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SHOCK: CAUSES AND EPIDEMIOLOGY
Shock may be defined as the failure of the circulation to
provide sufficient blood and oxygen to peripheral organs. Key
symptoms of shock are severe hypotension and vasoplegia,
ultimately resulting in the dysfunction of one or more vital
organs, such as kidney, liver, gut, lung, and brain. Life-
threatening shock may be caused by acute myocardial
infarction (cardiogenic shock), severe fluid or blood loss
(hypovolemic or hemorrhagic shock), severe infection (septic
shock), or severe allergic reaction (anaphylactic shock). The
most common type of shock is hemorrhagic shock; in
children, elderly, and immunocompromized people, septic
shock is the most common. In the first week after diagnosis,
refractory hypotension is the leading cause of death; later on,
death is generally caused by multiple organ failure as a result
of prolonged hypotension and cytotoxicity. The history of
clinical trials in septic patients extends back to 1963, when
high-dose hydrocortisone was used.1 But despite almost half
a century of clinical trials, and more than two decades of
extensive research, only two experimental approaches have
survived the numerous clinical trials and have reached the
septic patient: low-dose corticosteroids and recombinant
human activated protein C.1,2 Still, their beneficial effect on
survival seems to depend on the severity of the illness and
they may be rather harmful in patients with a lower risk of
death.2 In addition, recent trials failed to show any significant
benefit of recombinant human activated protein C and
indicated an increased risk of bleeding, making it unclear
whether its alleged beneficial effects in fact outweigh its
risks.3 Thus, severe sepsis and septic shock are still associated
with an unacceptably high mortality rate of 50–70%. Short-
term mortality from septic shock has decreased in recent
years. In one study, for example, mortality fell from 62% in
the early 1990s to 56% in 2000.4 Nevertheless, overall
mortality is increasing, as the incidence of sepsis is growing
by 9% each year.4,5 Consequently, these days more people die
annually from septic shock than from myocardial infarction,
lung or breast cancer, stroke, or trauma.6 Anaphylaxis can
occur in response to any allergen, most commonly insect
stings, food, and drugs such as antibiotics, contrast materials,
and anesthetics. In general, about 1% of people with an
allergic history are prone to anaphylaxis, but some authors
consider up to 15% of the US population ‘at risk’.7 Overall,
the frequency of anaphylaxis is increasing because of the
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soaring incidence of allergies and the increased number of
potential allergens to which people are exposed.
NITRIC OXIDE: HISTORY AND BACKGROUND
In 1980, Furchgott and Zawadzki8 reported that endothelial
cells release a labile factor that causes blood vessel relaxation.
In 1986, it was suggested, and subsequently confirmed, that
this endothelial-derived relaxing factor is the short-lived,
gaseous, highly reactive radical nitric oxide (NO).9–13
NO is produced enzymatically by three different NO
synthases (NOS). Neuronal NOS (nNOS) (NOS1) and
endothelial NOS (eNOS) (NOS3) are constitutive enzymes
important for homeostatic processes, such as neurotransmis-
sion and vascular tone, respectively. They produce small
amounts of NO in response to increases in intracellular
calcium. More recently, the constitutive nature of eNOS has
achieved new dimensions, as it became clear that the
enzyme’s activity may be regulated, both transcriptionally
and post-transcriptionally, with acylation, phosphorylation,
subcellular localization, and protein interactions determining
its activity.14 The third enzyme, inducible NOS (iNOS)
(NOS2), is normally not expressed, but is synthesized de novo
in response to inflammation. It is calcium-independent and
produces large amounts of NO over prolonged periods of
time.15 NOS enzymes make NO from L-arginine, and thus
competitive L-arginine analogues may prevent them from
producing NO. These analogues include NG-monomethyl-L-
arginine (L-NMMA), NG-nitro-L-arginine (L-NNA), and NG-
nitro-L-arginine methyl ester (L-NAME). As early as 1989,
some of these compounds were already successfully used to
demonstrate the important physiological role of NO in
normal blood pressure homeostasis.16,17
NO IN SEPTIC SHOCK: CRITICAL MEDIATOR OF HYPOTENSION
Shortly after the discovery that NO is an important
endogenous regulator of vascular tone, its fundamental
contribution to inflammatory and septic shock became
obvious as well. The NO metabolites nitrite and nitrate
(collectively labeled NOx
), indicators of NO production, rise
progressively in various animal shock models.18 In small
rodents, plasma concentrations of hundreds to even thou-
sands micromolar may be detected. In larger mammals and
humans, however, overproduction does not occur to the
same extent and levels rarely increase above 100 mM, or more
than 50% above background, despite major circulatory
failure.18 Nevertheless, the critical role of NO in shock has
been clearly established, as NOS inhibitors prevent, revert, or
at least minimize hypotension in shock induced by
lipopolysaccharide (LPS), tumor necrosis factor (TNF),
interleukin-1, interleukin-2, or hemorrhage.19–24 NOS in-
hibition also successfully and rapidly elevates blood pressure
and systemic vascular resistance in septic shock patients.25–28
The first studies on NOS inhibition immediately triggered
great hopes for a new treatment of refractory hypotension in
(septic) shock, but even the earliest studies already indicated
the potential harm of NOS inhibitors, as they also caused a
progressive fall in cardiac output, amplified organ dysfunc-
tion, and even increased mortality.26,29–33 Exacerbated organ
damage was first reported for the kidney,31 but later studies
revealed increased injury in other organs as well, including
liver, lung, pancreas, and intestines.18 Unfortunately, even a
phase III clinical trial had to be prematurely terminated
because of increased mortality in the septic patients treated
with the NOS inhibitor, despite positive effects on blood
pressure and vascular resistance.28 Together, these observa-
tions clearly indicate that NO not only mediates hypotension
in septic shock, but may also perform an important
obligatory role in assorted beneficial pathways.
NO IN SEPTIC SHOCK: DETRIMENTAL VERSUS BENEFICIAL
EFFECTS
Different explanations may be suggested for the dual
personality of NO during septic shock. First of all, there is
no doubt about the detrimental effect of excessive NO on
vasorelaxation, hypotension, and shock. The NO-mediated
hypotension leads to severe hypoxia in peripheral vital
organs, resulting in progressive organ failure. NO may also
directly contribute to tissue and organ injury by its direct,
peroxynitrite-mediated cytotoxic effects. It is generally
accepted that NO may cause blood vessel relaxation by
activating the cyclic guanosine monophosphate (cGMP)-
producing enzyme soluble guanylate cyclase (sGC), leading
to activation of the cGMP-dependent protein kinases (PKGs).
For smooth muscle contraction, calcium-dependent activa-
tion of the myosin light chain (MLC) kinase and subsequent
phosphorylation of MLC are essential. Several PKG-depen-
dent phosphorylations ultimately converge on the dephos-
phorylation of MLC and hence relaxation34 (Figure 1).
Important molecular targets of PKG include various pumps
and channels involved in modulating intracellular calcium
levels and membrane potential, leading to decreased cytosolic
calcium and relaxation. In addition to changes in intracel-
lular calcium levels and membrane potential, other impor-
tant targets for PKG in smooth muscle are the pathways
regulating the calcium-sensitivity of the contractile machin-
ery, more particularly the regulatory subunit of MLC
phosphatase, which may be directly activated by PKG or
indirectly via PKG-mediated inactivation of the inhibitory
RhoA pathway.35,36 Nevertheless, NO may also contribute
independently of sGC and PKG to lower cytosolic calcium
levels, for instance via direct S-nitrosation of potassium
channels,37 via NO-dependent peroxynitrite-mediated S-
glutathiolation of the sarco/endoplasmic reticulum calcium
adenosine triphosphatase (ATPase) (SERCA) pump,38 or via
direct inhibition of cytochrome P450 (CYP). Enzymes of the
CYP4A family are known to produce the vasoconstrictor 20-
HETE, an inhibitor of BK channels.39 Although sGC has long
been regarded as the predominant target for NO in the
vasculature, the notion and importance of sGC-independent
actions has gained considerable interest lately. The sGC-
independent pathways would be especially important in
certain vascular beds (particularly in the renal and mesenteric
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vasculature), at high NO concentrations, and/or in the
presence of disease,40 suggesting that the sGC-independent
mechanisms may be important targets for drug development.
Second, increased NO may also provide certain benefits to
the patient during septic shock. Arterial vasodilation results
in arterial underfilling, which is rapidly sensed by the
baroreceptors, thereby leading to increased sympathetic
outflow and the activation of the renin–angiotensin–aldoster-
one system. This leads to vasopressin release, renal vasocon-
striction and kidney failure, an acute problem in most septic
shock patients, which is associated with very high mortality.41
In this context, increased NO release protects the kidney by
causing local vasodilation and by inhibiting platelet aggrega-
tion and leukocyte adhesion. In addition, NO may also exert
protective effects in other organs via its capacity to counter-
act oxidative stress, shut off apoptosis, prevent platelet
aggregation and leukocyte adhesion, induce anti-inflamma-
tory gene expression, and kill pathogens.
NO IN SEPTIC SHOCK: WHAT IS ITS SOURCE?
Originally it was thought that the dual, Janus-faced effects of
NO would relate to the NOS isoform responsible for its
production, with eNOS providing the essential, protective
NO and iNOS causing excessive vasodilation. For a long time,
leukocyte iNOS was thus thought to be responsible for the
production of shock-inducing NO. The reasons for this
assumption are obvious: when iNOS is transcribed, it
produces large amounts of NO for a long time.15 In addition,
rodent macrophages may be induced to produce large
amounts of NO in vitro;42 iNOS was originally identified as
‘macrophage’ NOS;43 and although human macrophages do
not seem to be capable of producing much NO in vitro or ex
vivo,44,45 neutrophils from septic patients display abnormally
high amounts of iNOS mRNA activity.46,47 More recently,
however, it was demonstrated in mice that parenchymal cells,
rather than blood cells, are required for the systemic
production of NO during septic and endotoxic shock.48
Tissues that do express high levels of iNOS during
endotoxemia or bacteremia were identified as liver and
intestines.48,49 Whether hepatocytes, enterocytes, Paneth
cells, or rather vascular cells are the predominant parench-
ymal source of the enhanced systemic NO, remains to be
determined. Studying cell-specific iNOS-deficient or iNOS-
reactivation mice may provide the answer to this question.
In well-oxygenated conditions, NOS enzymes may produce
NO from L-arginine. Some of this NO reaches its targets, such
as the smooth muscle cells where it triggers relaxation, but the
majority is destroyed by rapid oxidation into nitrite and
nitrate. Until recently, these metabolites were considered to be
physiologically inert, stable end products, and an index of NO
production. However, substantial proof is now emerging that
plasma nitrite actually serves as an important vascular storage
pool for NO.50 Previously, it was suggested that S-nitrosated
albumin and hemoglobin were the stable transporters of
intravascular NO.51,52 However, the levels of circulating S-
nitrosothiols are either undetectable or in the lower nM range,
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Figure 1 | Schematic of possible molecular mechanisms of
NO-mediated vascular relaxation. NO may be enzymatically
produced by eNOS, iNOS, or via nitrite (NO2
) reduction by
deoxygenated heme-globins, xanthine oxidase, mitochondria, or
acidic disproportionation. Vasoactive agonists normally elevate
intracellular Ca2þ concentrations in endothelial cells, thus
stimulating eNOS activity. In addition, fluid shear stress, estrogen,
insulin, or inflammatory signals may cause PI3K/Akt-dependent
phosphorylation of eNOS, resulting in its increased catalytic activity at
basal Ca2þ levels. Various inflammatory stimuli, such as LPS or TNF,
also trigger de novo transcription of the Ca2þ -independent inducible
iNOS enzyme, resulting in the production of large amounts of NO for
a prolonged period of time. For reasons of simplicity, the production
of NO was depicted only in the endothelial cell, but may of course
also occur in the smooth muscle cell, especially in inflammatory
conditions. In the smooth muscle cell, NO may cause relaxation by a
myriad of actions reducing cytosolic Ca2þ levels on the one hand
and the sensitivity of the contractile apparatus for Ca2þ on the other.
Independent of sGC, NO can directly S-nitrosate and activate Kþ
channels, causing Kþ efflux, membrane hyperpolarization, and thus a
decrease in voltage-dependent Ca2þ entry. NO may also
sGC-independently inhibit the CYP4A-dependent production of
20-HETE, an inhibitor of BK channel activity. In addition, through its
reaction with superoxide to form peroxynitrite, NO may cause
glutathione (GSH) to bind to and activate the sarcoplasmic reticulum
Ca2þ ATPase (SERCA), which takes up cytosolic Ca2þ . Nevertheless,
many of the relaxing effects of NO are the result of its binding to
Fe2þ -heme in sGC, resulting in a conformational change that
activates the enzyme, increasing cGMP levels and PKG activity. PKG-
mediated phosphorylation may cause (1) activation of Kþ channels
and hyperpolarization; (2) inhibition of L-type Ca2þ channels and
Ca2þ influx; (3) increased Ca2þ efflux through activation of the
Ca2þ Mg2þ ATPase and (4) the Naþ /Ca2þ exchanger; (5) Ca2þ
sequestration through SERCA activation; (6) reduction of Ca2þ
mobilization through the inhibition of the sarcoplasmic reticulum IP3
receptor or the phospholipase C-dependent formation of IP3 (data
not shown); or activation of the MLC phosphatase. (7) The latter may
be achieved directly via phosphorylation of the MLC phosphatase
or indirectly via inhibition of the inactivating RhoA pathway (data
not shown), ultimately resulting in dephosphorylation of the
vasoconstricting MLC.
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whereas nitrite is present in concentrations of 0.5–1mM.50,53 In
addition, nitrite is more stable in blood and it seems that most
of it is carried by erythrocytes. The reduction of nitrite back to
the vasodilating NO occurs preferentially under hypoxic and/
or acidic conditions and may be catalyzed by deoxyhemoglo-
bin, xanthine oxidase, or mitochondrial enzymes50 (Figure 1).
In this way, nitrite derived from either dietary nitrite or nitrate
(the latter further reduced by commensal bacteria) or from the
oxidation of NOS-produced NO, may have an important
function in the endocrine delivery of NO to hypoxic/acidic
regions that need vasodilation.
NO IN SEPTIC SHOCK: SELECTIVE iNOS INHIBITORS AS
THERAPEUTICS?
The dichotomous effects of NO present one of the biggest
challenges to the development of potential therapeutic
inhibitors. General inhibition of NOS enzymes improves
hemodynamic functions but increases mortality.28,30,32,33
Several arguments favor the development of selective iNOS
inhibitors to treat septic shock patients.
(1) The protective capacity of eNOS-derived NO in septic
conditions was underscored by the observation that
transgenic overexpression of eNOS partly protected
mice from LPS.54 More recently, mice with a cardio-
myocyte-specific overexpression of eNOS were also
partially protected against both endotoxemia and
polymicrobial sepsis.55
(2) Sepsis may cause an iNOS-dependent decrease in eNOS
expression and activity,56 causing endothelial dysfunc-
tion and impaired microvascular homeostasis, which
may be particularly important in the kidney.
(3) In animals, most studies using selective iNOS inhibitors
did not report deleterious effects like those observed
with the nonselective NOS inhibitors; sometimes they
even reported protective effects on organ failure or
mortality. However, several models also failed to show
beneficial effects of iNOS inhibition and, to be
complete, a few reports even described deleterious
effects on lung or liver injury.18 Nevertheless, despite
some conflicting results on the effects of iNOS
inhibition on organ damage or outcome, circulatory
failure was prevented or reverted in all studies.
However, we should not forget that, in contrast to iNOS-
specific inhibitory drugs, iNOS-deficient mice are not at all
protected against endotoxemia, sepsis, or TNF-induced
shock. On the contrary, most studies even reported increased
mortality,57–61 suggesting that iNOS actually grants a survival
advantage. This protective effect of iNOS might be due to the
antiapoptotic or antioxidative activities of induced NO.62,63
Indeed, both in vitro and in vivo, NO has been documented
to efficiently interfere with lipid peroxidation.61,64,65 The
differences in the effects of iNOS inhibitors versus iNOS-
deficiency may have several reasons.
(1) iNOS inhibitors could have additional pharmacological
effects unrelated to iNOS inhibition. S-methyl-iso-
thiourea, for example, also has antioxidative effects,66
whereas aminoguanidine inhibits catalase activity.67
(2) It may be more important to merely downregulate (via
pharmacological inhibitors), but not completely annul,
iNOS activity, so that residual NO produced by iNOS
may exert its necessary protective functions.
(3) Alternatively, the beneficial versus detrimental func-
tions of iNOS might be linked to its induction in
certain tissues or cells, which would warrant the
development of cell-specific iNOS inhibitors. One
could imagine that iNOS inhibitors injected systemi-
cally might reach selected tissues or cellular compart-
ments more easily than others, such that iNOS activity
in certain protective environments remains, while its
activity in other locations, for example those that are
more easily reached and that are also important for
shock induction, is efficiently abrogated.
NO IN SEPTIC SHOCK: NO SCAVENGERS AS THERAPEUTICS?
Despite their preference for iNOS, most of the so-called
selective iNOS inhibitors that are currently available still
retain some activity against other NOS isoforms. In addition,
NO may also be produced independently of NOS activity, for
instance via the reduction of nitrite.50 Therefore, the
therapeutic use of compounds that selectively scavenge
excessive NO, without interfering with NOS expression or
activity, seems interesting. Theoretically, these scavengers
might prevent toxicity and/or shock caused by excessive NO,
while preserving some essential NO activities in the
proximity of its area of production.
Various NO-scavenging compounds have been identified,
ranging from endogenous proteins such as hemoglobin, to
exogenous herbal substances, medications, nitronyl nitroxides
such as carboxy-PTIO, and spin-trapping probes such as
dithiocarbamate derivatives.68 Some of these compounds have
been proposed as efficient NO scavengers in various animal
models of sepsis, reducing hypotension, organ dysfunction,
bacterial translocation, and mortality.69–73 Some NO scaven-
gers have even entered clinical trials, such as the chemically
modified human-derived hemoglobin conjugate pyridoxalated
hemoglobin polyoxyethylene (PHP), which demonstrated its
potential to increase systemic blood pressure and reduce
vasopressor and ventilation needs without adverse effects on
cardiac output, organ damage, or survival.74,75 Based on these
promising results, a phase III trial has recently been conducted,
but was not yet published. However, just like the perfectly
selective iNOS inhibitor, the optimal NO-scavenging com-
pound (specific for NO radicals only, with appropriate
solubility and half-life) has yet to be developed.68
NO IN SEPTIC SHOCK: TARGET DOWNSTREAM MEDIATORS?
Because even specific iNOS inhibition is not always
associated with diminished organ damage and/or mortality
in experimental endotoxic or septic shock, it might be
necessary to shift gears in our approach to successful
560 Kidney International (2007) 72, 557–565
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therapeutics. A safer and more rational approach could be
the selective modulation of certain specific downstream
targets of NO that are known to perform an important role
in its hypotensive effects. This way, only the shock-inducing
effects of NO, and not its production, would be affected and
its beneficial and antimicrobial effects could still carry on.
As mentioned before, sGC is generally regarded as the
principal intracellular NO receptor in the cardiovascular
system (Figure 1). Binding of NO results in a B200-fold
activation of sGC, leading to cGMP accumulation and
cGMP-dependent cardiovascular changes, such as vascular
relaxation, myocardial depression, and inhibition of platelet
aggregation and adhesion.34 One possibly safer therapeutic
option could thus be the selective inhibition of sGC in shock.
This approach seems especially attractive in view of the
possibility that NO-independent activation of sGC could also
contribute to shock.76,77 On the other hand, there is also
increasing evidence that sGC-independent mechanisms may
contribute significantly, and in certain vascular beds,
conditions, or diseases even predominantly, to NO-induced
relaxation.40 To inhibit sGC activation, methylene blue (MB),
a chemical dye whose safety in humans has been proven, has
been used in both experimental and clinical shock trials.
Although MB can improve hemodynamics in both endotoxic
and TNF-induced shock,60,78,79 it can only provide protection
in TNF-induced shock60 and not against endotoxemia
(Cauwels et al., submitted). Analogously, MB infusion in
humans suffering septic shock reverses hypotension, but does
not change the overall course or the mortality rate.80–84 It
should be noted that MB not only prevents sGC activation, it
also (partially) inhibits NOS enzymes and oxidative stress.84–87
1H-(1,2,4)oxadiazolo (4,3-a)quinoxalin-1-one (ODQ), a more
selective and potent inhibitor of sGC 88–90 which may still inhibit
NOS,40,91 but has no effect on O2
K or KOH production or
scavenging,92 is not capable of reverting endotoxic hypoten-
sion92,93 or TNF-induced mortality (Cauwels et al., unpublished
data), in contrast to MB.60,78,79 Hence, it seems possible that the
protective hemodynamic effects of MB might be attributed to its
non-sGC-dependent effects on oxidative stress. However, the
inability of ODQ to prevent shock should be appraised with
some caution, as the efficiency of ODQ to inhibit sGC activation
in vivo is sometimes doubted because of its relatively rapid
reaction with oxyhemoglobin.89 Although the different effects of
MB and ODQ might indicate a possible role for O2
K or KOH
in shock, these radicals have not really been implicated in
vasorelaxation or shock so far.
Another possible target downstream of NO is the
inhibition of Kþ channels, as NO may activate different
Kþ channels both sGC-dependently and -indepen-
dently37,94–96 (Figure 1). The most important Kþ channel
subclasses in the vasculature that are involved in the action of
various endothelium-derived relaxing factors are the ATP-
sensitive KATP channel and the large conductance calcium-
activated BK channel. KATP channels have long been
suspected of playing the most important role in septic shock
because of their metabolic sensitivity.97,98 They are activated
by decreased ATP, increased lactate, or acidosis, all of which
characterize sepsis. In addition, they may also be activated by
NO, prostacyclin (PGI2), or the more recently identified
vasodilator hydrogen sulfide (H2S).
94,97,99 In many endotoxic
animal models, KATP inhibition by parenteral glibenclamide
could, at least partially, revert hypotension or vascular
hyporesponsiveness.100–103 However, glibenclamide did not
restore responsiveness in all animal studies104 or in a recent
clinical trial.105 Although the failure in the latter might
have been due to administration of the drug by the enteral
route or to the mild lactic acidosis in the enrolled patients,106
the results imply that KATP inhibition might not be the
appropriate treatment for septic shock.
Very recently, attention has also drifted towards the
inhibition of BK channels to treat shock, as they are probably
the most important channels involved in NO-dependent
relaxation.94,96 NO may activate BK channels not only sGC-
dependently, through phosphorylation by cGMP-dependent
PKG, but also sGC-independently via direct S-nitrosation
and activation of BK channels37,40,107,108 or via inhibiting the
production of the BK inhibitor 20-HETE39,40 (Figure 1). In
addition, BK channels are also targeted by other potential
vasodilators, including H2O2 and epoxyeicosatrienoic
acids.109–111 Studies with BK inhibitors are scarce and none
of them have used specific BK-inhibiting drugs, but rather
tetraethylammonium, a nonspecific inhibitor of BK, KATP,
and certain voltage-gated Kv channels. Tetraethylammonium
restored vascular responsiveness in one study,104 but failed to
improve blood pressure or mortality in another.112 However,
since tetraethylammonium could also restore vasopressor
responses in an experimental human endotoxemia study,113
high hopes are set for the modulation of BK channels as a
potential therapy.
BK channels exhibit a very high conductance for Kþ ions,
they are abundant in smooth muscle, and they are activated
by the concerted influence of membrane depolarization and
elevated intracellular Ca2þ levels.114 However, they are not
the only calcium-dependent Kþ channels. Small (SK) and
intermediate (IK) conductance calcium-activated Kþ chan-
nels also exist. In contrast to the BK channels, they are not
voltage-dependent. Because the BK channel is activated both
directly and indirectly by NO, it has received most of the
attention so far. Interestingly, however, the two other
calcium-gated channels were implicated in the action and/
or the effect of another vasodilating phenomenon: endo-
thelium-derived hyperpolarizing factor (EDHF). EDHF is
defined as the hyperpolarizing and relaxing effect that
remains when NO and PGI2 production are inhibited and
its contribution to vasodilation appears to be especially
significant in smaller, resistance vessels.111 Despite two
decades of research, the molecular identity of EDHF remains
controversial. Over the years, several candidates have been
proposed, discussed, questioned, and refuted.111 Despite that,
it is universally accepted that the hyperpolarizing effect of
EDHF depends strictly on SK channels, often assisted by IK
channels.115–117 A physiological, gender-dependent role for
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EDHF in vascular tone was recently suggested,118 but the
question remains whether EDHF actively participates in
physiological or pathological blood pressure regulation or
whether it is merely a backup mechanism observed only
when the production of NO and PGI2 is eliminated or fails.
In addition, the involvement of EDHF in pathologies such as
shock has not been suggested or studied so far. Intriguingly,
specific SK channel inhibition by apamin can provide a
substantial survival advantage in both TNF- and LPS-
induced shock in mice, especially when combined with BK-
channel inhibition and MB (Cauwels et al., submitted), and
may be well worth pursuing as a future therapeutic option.
SEPTIC SHOCK: OTHER VASORELAXING THERAPEUTIC
TARGETS?
The ability of NOS inhibitors to prevent or revert hypoten-
sion in shock induced by LPS, TNF, interleukin-1, inter-
leukin-2, hemorrhage, and sepsis is clear evidence for the
pivotal and essential role NO plays in the development of
hypotension during inflammation-associated shock.19–28
However, some observations also indicate that NO might
not be the only important shock-inducing factor. Indeed, the
elevation of circulating NOx
 is relatively modest in large
mammals and humans18 and seems not even obligatory in
severe sepsis.119 Moreover, in cancer patients receiving
isolated limb perfusion with the anticancer agent TNF,
complicated by leakage from the perfusion circuit to the
general circulation, no systemic NO metabolites were found,
despite substantial hypotension.120 Therefore, other (still
unknown?) vasodilating factors might be just as important as
NO in causing systemic hypotension and shock.
As already mentioned, the possibility that the molecularly
unidentified EDHF is implicated has not been evaluated yet.
Until there is consensus on the molecular identity of EDHF,
its synthesis cannot be specifically or selectively blocked and
its role in shock cannot be easily studied. An alternative
approach to investigate the possible contribution of EDHF
could be the analysis of the importance of the various
calcium-dependent Kþ channels. In this regard, the involve-
ment of SK channels in TNF- and LPS-induced shock might
be indicative of a possible contribution by EDHF (Cauwels
et al., submitted).
Another recently characterized endogenous vasodilator is
the gaseous molecule H2S, which causes vascular smooth
muscle relaxation by acting on KATP channels and synergizes
with NO to induce vessel relaxation.99,121 In vascular smooth
muscle cells, H2S is formed by the hydrolysis of L-cysteine by
cystathionine-g-lyase. Inhibition of cystathionine-g-lyase may
prevent organ damage and mortality in experimental
endotoxemia and sepsis,122–124 but it cannot revert endotoxic
hypotension.123
It is generally understood that therapeutic interventions to
modulate oxidative stress in septic shock are worthwhile to be
pursued, especially in terms of preventing tissue damage and
organ failure caused by reactive radicals such as O2
K, KOH,
and ONOO.125–127 As already alluded to earlier in this
review, the conflicting effects of the sGC inhibitors MB and
ODQ on LPS- or TNF-induced hypotension and
shock60,78,79,92,93 could indicate the involvement of oxygen
radicals such as O2
K or KOH. The ability of these radicals to
cause vasorelaxation, or to contribute to hypotension and
shock, has not been extensively explored yet, but is definitely
worth investigating.
NO IN ANAPHYLACTIC SHOCK
Anaphylaxis is a sudden and severe systemic allergic reaction
that often occurs in the absence of a history of allergy.
Allergens that commonly cause anaphylaxis include
medications, such as penicillins, radiocontrast media and
anesthetics, and foods such as nuts, fish, and shellfish as
well as insect stings, exposure to latex, and exercise.
Anaphylaxis is not as rare as generally believed and may
affect as much as 1–15% of the population.7 In addition,
the prevalence of anaphylaxis is increasing significantly.
During an anaphylactic reaction, severe cardiovascular or
pulmonary dysfunction often leads to death, with acute
hypotension as the most important clinical feature. Once an
anaphylactic reaction has begun, the treatment of choice
is an instantaneous injection of adrenaline, followed by
emergency medical attention. To date, supportive adrenalin
and large-volume intravenous fluid resuscitation are the only
available treatments. Unfortunately, severe hemodynamic
collapse during anaphylaxis is often resistant to this
treatment.128,129
The possible contribution of NO to anaphylactic shock
has been studied before. Although NOS inhibition partially
reduced anaphylactic mortality in an early study,130 it
decreased survival time and rate in most other studies.131,132
However, these studies were performed in animals under
general anesthesia, which influences NO-mediated effects and
blood pressure changes. More recently, the critical role of NO
in anaphylactic shock was unequivocally demonstrated in
conscious, nonanesthetized mice: pretreatment with the NOS
inhibitor L-NAME successfully prevented both hypotension
and mortality.133 Surprisingly, this crucial NO was not
produced by iNOS, but by the so-called constitutive isoform
eNOS, which may be rapidly phosphorylated and activated
via the PI3K/Akt pathway to produce large amounts of
NO (Figure 1). In mice treated with inhibitors of PI3K, Akt,
or NOS as well as in eNOS-deficient animals, anaphylaxis-
induced hypothermia and hypotension were mild and
transient and no deaths occurred. Despite the pivotal
role for eNOS-produced NO, there seemed to be no
significant involvement of sGC.133 All in all, this study
clearly indicated that PI3K/Akt-activated eNOS-derived NO
is a pivotal vasodilator in anaphylactic shock and that
selective and fast-acting inhibitors of any of these molecules
may provide new, specific tools for the treatment of
anaphylactic shock.
ACKNOWLEDGMENTS
AC is a postdoctoral fellow of the FWO-Vlaanderen.
562 Kidney International (2007) 72, 557–565
r e v i e w A Cauwels: Nitric oxide in shock
REFERENCES
1. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of
sepsis. Nat Med 2003; 9: 517–524.
2. Deans KJ, Haley M, Natanson C et al. Novel therapies for sepsis: a review.
J Trauma 2005; 58: 867–874.
3. Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC
may outweigh its benefits. Intensive Care Med 2007; 33: 396–399.
4. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365:
63–78.
5. Martin GS, Mannino DM, Eaton S et al. The epidemiology of sepsis in the
United States from 1979 through 2000. N Engl J Med 2003; 348:
1546–1554.
6. Nguyen HB, Rivers EP, Abrahamian FM et al. Severe sepsis and septic
shock: review of the literature and emergency department management
guidelines. Ann Emerg Med 2006; 48: 28–54.
7. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an
investigation into its epidemiology. Arch Intern Med 2001; 161: 15–21.
8. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the
relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:
373–376.
9. Furchgott R. Studies on relaxation of rabbit aorta by sodium nitrite: the
basis for the proposal that the acid-activatable inhibitory factor from
retractor penis is inorganic nitrate the endothelium-derived relaxing
factor is nitric oxide. In: Vanhoutte PM (ed). Vasodilatation: Vascular
Smooth Muscle, Peptides, Autonomic Nerves, and Endothelium. New York:
Raven Press, 1988: 401–414.
10. Ignarro LJ, Burns R, Wood K. Biochemical pharmacological properties of
EDRF its similarity to nitric oxide. In: Vanhoutte PM (ed). Vasodilatation:
Vascular Smooth Muscle, Peptides, Autonomic Nerves, and Endothelium.
New York: Raven Press, 1988: 427–435.
11. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the
biological activity of endothelium-derived relaxing factor. Nature 1987;
327: 524–526.
12. Ignarro LJ, Buga GM, Wood KS et al. Endothelium-derived relaxing factor
produced and released from artery and vein is nitric oxide. Proc Natl
Acad Sci USA 1987; 84: 9265–9269.
13. Ignarro LJ, Byrns RE, Buga GM et al. Endothelium-derived relaxing factor
from pulmonary artery and vein possesses pharmacologic and chemical
properties identical to those of nitric oxide radical. Circ Res 1987; 61:
866–879.
14. Fleming I, Busse R. Molecular mechanisms involved in the regulation of
the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp
Physiol 2003; 284: R1–R12.
15. Morris Jr SM, Billiar TR. New insights into the regulation of inducible
nitric oxide synthesis. Am J Physiol 1994; 266: E829–E839.
16. Aisaka K, Gross SS, Griffith OW et al. NG-methylarginine, an inhibitor of
endothelium-derived nitric oxide synthesis, is a potent pressor agent in
the guinea pig: does nitric oxide regulate blood pressure in vivo?
Biochem Biophys Res Commun 1989; 160: 881–886.
17. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric
oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;
86: 3375–3378.
18. Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of
choice for the management of septic shock? Pharmacol Ther 2001; 91:
179–213.
19. Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the
hypotension induced by bacterial lipopolysaccharides in the rat in vivo.
Eur J Pharmacol 1990; 182: 591–595.
20. Kilbourn RG, Jubran A, Gross SS et al. Reversal of endotoxin-mediated
shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis.
Biochem Biophys Res Commun 1990; 172: 1132–1138.
21. Kilbourn RG, Gross SS, Jubran A et al. NG-methyl-L-arginine inhibits
tumor necrosis factor-induced hypotension: implications for the
involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87:
3629–3632.
22. Kilbourn RG, Gross SS, Lodato RF et al. Inhibition of
interleukin-1-alpha-induced nitric oxide synthase in vascular smooth
muscle and full reversal of interleukin-1-alpha-induced hypotension by
N omega-amino-L-arginine. J Natl Cancer Inst 1992; 84: 1008–1016.
23. Kilbourn RG, Fonseca GA, Griffith OW et al. NG-methyl-L-arginine, an
inhibitor of nitric oxide synthase, reverses interleukin-2-induced
hypotension. Crit Care Med 1995; 23: 1018–1024.
24. Thiemermann C, Szabo C, Mitchell JA et al. Vascular hyporeactivity to
vasoconstrictor agents and hemodynamic decompensation in
hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci USA
1993; 90: 267–271.
25. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors
on hypotension in patients with septic shock. Lancet 1991; 338:
1557–1558.
26. Petros A, Lamb G, Leone A et al. Effects of a nitric oxide synthase
inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34–39.
27. Avontuur JA, Tutein Nolthenius RP, van Bodegom JW et al. Prolonged
inhibition of nitric oxide synthesis in severe septic shock: a clinical study.
Crit Care Med 1998; 26: 660–667.
28. Lopez A, Lorente JA, Steingrub J et al. Multiple-center, randomized,
placebo-controlled, double-blind study of the nitric oxide synthase
inhibitor 546C88: effect on survival in patients with septic shock. Crit
Care Med 2004; 32: 21–30.
29. Klabunde RE, Ritger RC. NG-monomethyl-L-arginine (NMA) restores
arterial blood pressure but reduces cardiac output in a canine
model of endotoxic shock. Biochem Biophys Res Commun 1991; 178:
1135–1140.
30. Cobb JP, Natanson C, Hoffman WD et al. N omega-amino-L-arginine, an
inhibitor of nitric oxide synthase, raises vascular resistance but increases
mortality rates in awake canines challenged with endotoxin. J Exp Med
1992; 176: 1175–1182.
31. Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents
endotoxin-induced glomerular thrombosis. J Clin Invest 1992; 90:
1718–1725.
32. Teale DM, Atkinson AM. L-canavanine restores blood pressure in a rat
model of endotoxic shock. Eur J Pharmacol 1994; 271: 87–92.
33. Liaudet L, Rosselet A, Schaller MD et al. Nonselective versus selective
inhibition of inducible nitric oxide synthase in experimental endotoxic
shock. J Infect Dis 1998; 177: 127–132.
34. Lucas KA, Pitari GM, Kazerounian S et al. Guanylyl cyclases and signaling
by cyclic GMP. Pharmacol Rev 2000; 52: 375–414.
35. Schlossmann J, Hofmann F. cGMP-dependent protein kinases in drug
discovery. Drug Discov Today 2005; 10: 627–634.
36. Murthy KS. Signaling for contraction and relaxation in smooth muscle of
the gut. Annu Rev Physiol 2006; 68: 345–374.
37. Bolotina VM, Najibi S, Palacino JJ et al. Nitric oxide directly activates
calcium-dependent potassium channels in vascular smooth muscle.
Nature 1994; 368: 850–853.
38. Adachi T, Weisbrod RM, Pimentel DR et al. S-glutathiolation by
peroxynitrite activates SERCA during arterial relaxation by nitric oxide.
Nat Med 2004; 10: 1200–1207.
39. Roman RJ. P-450 metabolites of arachidonic acid in the control of
cardiovascular function. Physiol Rev 2002; 82: 131–185.
40. Wanstall JC, Homer KL, Doggrell SA. Evidence for, and importance of,
cGMP-independent mechanisms with NO and NO donors on blood
vessels and platelets. Curr Vasc Pharmacol 2005; 3: 41–53.
41. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;
351: 159–169.
42. Stuehr DJ, Marletta MA. Mammalian nitrate biosynthesis: mouse
macrophages produce nitrite and nitrate in response to Escherichia coli
lipopolysaccharide. Proc Natl Acad Sci USA 1985; 82: 7738–7742.
43. Stuehr DJ, Cho HJ, Kwon NS et al. Purification and characterization of
the cytokine-induced macrophage nitric oxide synthase: an FAD- and
FMN-containing flavoprotein. Proc Natl Acad Sci USA 1991; 88:
7773–7777.
44. Denis M. Human monocytes/macrophages: NO or no NO? J Leukoc Biol
1994; 55: 682–684.
45. Albina JE. On the expression of nitric oxide synthase by human
macrophages. Why no NO? J Leukoc Biol 1995; 58: 643–649.
46. Tsukahara Y, Morisaki T, Horita Y et al. Expression of inducible nitric
oxide synthase in circulating neutrophils of the systemic inflammatory
response syndrome and septic patients. World J Surg 1998; 22:
771–777.
47. Goode HF, Howdle PD, Walker BE et al. Nitric oxide synthase activity is
increased in patients with sepsis syndrome. Clin Sci (Lond) 1995; 88:
131–133.
48. Bultinck J, Sips P, Vakaet L et al. Systemic NO production during (septic)
shock depends on parenchymal and not on hematopoietic cells: in vivo
iNOS expression pattern in (septic) shock. FASEB J 2006; 20: 2363–2365.
49. Hickey MJ, Sihota E, Amrani A et al. Inducible nitric oxide synthase
(iNOS) in endotoxemia: chimeric mice reveal different cellular sources in
various tissues. FASEB J 2002; 16: 1141–1143.
50. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in
vascular control. Arterioscler Thromb Vasc Biol 2005; 25: 915–922.
51. Stamler JS, Jaraki O, Osborne J et al. Nitric oxide circulates in mammalian
plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl
Acad Sci USA 1992; 89: 7674–7677.
Kidney International (2007) 72, 557–565 563
A Cauwels: Nitric oxide in shock r e v i e w
52. Stamler JS, Jia L, Eu JP et al. Blood flow regulation by
S-nitrosohemoglobin in the physiological oxygen gradient. Science
1997; 276: 2034–2037.
53. Gladwin MT, Schechter AN. NO contest: nitrite versus
S-nitroso-hemoglobin. Circ Res 2004; 94: 851–855.
54. Yamashita T, Kawashima S, Ohashi Y et al. Resistance to endotoxin shock
in transgenic mice overexpressing endothelial nitric oxide synthase.
Circulation 2000; 101: 931–937.
55. Ichinose F, Buys ES, Neilan TG et al. Cardiomyocyte-specific
overexpression of nitric oxide synthase 3 prevents myocardial
dysfunction in murine models of septic shock. Circ Res 2007; 100:
130–139.
56. Chauhan SD, Seggara G, Vo PA et al. Protection against
lipopolysaccharide-induced endothelial dysfunction in resistance and
conduit vasculature of iNOS knockout mice. FASEB J 2003; 17: 773–775.
57. Laubach VE, Foley PL, Shockey KS et al. Protective roles of nitric oxide
and testosterone in endotoxemia: evidence from NOS-2-deficient mice.
Am J Physiol 1998; 275: H2211–H2218.
58. Nicholson SC, Grobmyer SR, Shiloh MU et al. Lethality of endotoxin in
mice genetically deficient in the respiratory burst oxidase, inducible
nitric oxide synthase, or both. Shock 1999; 11: 253–258.
59. Cobb JP, Hotchkiss RS, Swanson PE et al. Inducible nitric oxide synthase
(iNOS) gene deficiency increases the mortality of sepsis in mice.
Surgery 1999; 126: 438–442.
60. Cauwels A, Van Molle W, Janssen B et al. Protection against TNF-induced
lethal shock by soluble guanylate cyclase inhibition requires functional
inducible nitric oxide synthase. Immunity 2000; 13: 223–231.
61. Cauwels A, Bultinck J, Brouckaert P. Dual role of endogenous nitric oxide
in tumor necrosis factor shock: induced NO tempers oxidative stress. Cell
Mol Life Sci 2005; 62: 1632–1640.
62. Li CQ, Wogan GN. Nitric oxide as a modulator of apoptosis. Cancer Lett
2005; 226: 1–15.
63. Cauwels A, Brouckaert P. Survival of TNF toxicity: dependence on
caspases and NO. Arch Biochem Biophys 2007; 462 (doi:10.1016/
j.abb.2007.1001.1021).
64. Rubbo H, Radi R, Trujillo M et al. Nitric oxide regulation of superoxide
and peroxynitrite-dependent lipid peroxidation. Formation of novel
nitrogen-containing oxidized lipid derivatives. J Biol Chem 1994; 269:
26066–26075.
65. Rubbo H, Radi R, Anselmi D et al. Nitric oxide reaction with lipid peroxyl
radicals spares alpha-tocopherol during lipid peroxidation. Greater
oxidant protection from the pair nitric oxide/alpha-tocopherol than
alpha-tocopherol/ascorbate. J Biol Chem 2000; 275: 10812–10818.
66. Afulukwe IF, Cohen RI, Zeballos GA et al. Selective NOS inhibition
restores myocardial contractility in endotoxemic rats; however,
myocardial NO content does not correlate with myocardial dysfunction.
Am J Respir Crit Care Med 2000; 162: 21–26.
67. Nilsson BO. Biological effects of aminoguanidine: an update. Inflamm
Res 1999; 48: 509–515.
68. Harbrecht BG. Therapeutic use of nitric oxide scavengers in shock and
sepsis. Curr Pharm Des 2006; 12: 3543–3549.
69. Yoshida M, Akaike T, Wada Y et al. Therapeutic effects of imidazolineoxyl
N-oxide against endotoxin shock through its direct nitric oxide-
scavenging activity. Biochem Biophys Res Commun 1994; 202: 923–930.
70. Kaneda K, Yoshioka Y, Makita K et al. Effects of carboxy-PTIO on systemic
hemodynamics, liver energetics, and concentration of liver metabolites
during endotoxic shock in rabbits: a 31P and 1 H magnetic resonance
spectroscopic study. Crit Care Med 1997; 25: 1019–1029.
71. Bone HG, Fischer SR, Schenarts PJ et al. Continuous infusion of
pyridoxalated hemoglobin polyoxyethylene conjugate in hyperdynamic
septic sheep. Shock 1998; 10: 69–76.
72. Dickinson E, Tuncer R, Nadler E et al. NOX, a novel nitric oxide scavenger,
reduces bacterial translocation in rats after endotoxin challenge. Am J
Physiol 1999; 277: G1281–G1287.
73. Miura K, Yamanaka S, Ebara T et al. Effects of nitric oxide scavenger,
carboxy-PTIO on endotoxin-induced alterations in systemic
hemodynamics in rats. Jpn J Pharmacol 2000; 82: 261–264.
74. Privalle C, Talarico T, Keng T et al. Pyridoxalated hemoglobin
polyoxyethylene: a nitric oxide scavenger with antioxidant activity for
the treatment of nitric oxide-induced shock. Free Radic Biol Med 2000;
28: 1507–1517.
75. Kinasewitz G, Malcynski J, Steingrub J et al. Pyridoxalated hemoglobin
polyoxyethylene (PHP) in distributive shock. Crit Care Med 2004;
32(Suppl 12): A11.
76. Wu CC, Szabo C, Chen SJ et al. Activation of soluble guanylyl cyclase by
a factor other than nitric oxide or carbon monoxide contributes to the
vascular hyporeactivity to vasoconstrictor agents in the aorta of rats
treated with endotoxin. Biochem Biophys Res Commun 1994; 201:
436–442.
77. Wu CC, Chen SJ, Yen MH. Nitric oxide-independent activation of soluble
guanylyl cyclase contributes to endotoxin shock in rats. Am J Physiol
1998; 275: H1148–H1157.
78. Zhang H, Rogiers P, Preiser JC et al. Effects of methylene blue on oxygen
availability and regional blood flow during endotoxic shock. Crit Care
Med 1995; 23: 1711–1721.
79. Evgenov OV, Sveinbjornsson B, Bjertnaes LJ. Continuously infused
methylene blue modulates the early cardiopulmonary response to
endotoxin in awake sheep. Acta Anaesthesiol Scand 2001; 45: 1246–1254.
80. Schneider F, Lutun P, Hasselmann M et al. Methylene blue increases
systemic vascular resistance in human septic shock. Preliminary
observations. Intensive Care Med 1992; 18: 309–311.
81. Preiser JC, Lejeune P, Roman A et al. Methylene blue administration in
septic shock: a clinical trial. Crit Care Med 1995; 23: 259–264.
82. Kirov MY, Evgenov OV, Evgenov NV et al. Infusion of methylene blue in
human septic shock: a pilot, randomized, controlled study. Crit Care Med
2001; 29: 1860–1867.
83. Donati A, Conti G, Loggi S et al. Does methylene blue administration to
septic shock patients affect vascular permeability and blood volume?
Crit Care Med 2002; 30: 2271–2277.
84. Donati A, Preiser JC. Methylene blue: an old-timer or a compound ready
for revival? Crit Care Med 2006; 34: 2862–2863.
85. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by
methylene blue. Biochem Pharmacol 1993; 45: 367–374.
86. Salaris SC, Babbs CF, Voorhees III WD. Methylene blue as an inhibitor of
superoxide generation by xanthine oxidase. A potential new drug for
the attenuation of ischemia/reperfusion injury. Biochem Pharmacol
1991; 42: 499–506.
87. Kelner MJ, Bagnell R, Hale B et al. Potential of methylene blue to block
oxygen radical generation in reperfusion injury. Basic Life Sci 1988; 49:
895–898.
88. Garthwaite J, Southam E, Boulton CL et al. Potent and selective
inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 1995; 48:
184–188.
89. Moro MA, Russel RJ, Cellek S et al. cGMP mediates the vascular and
platelet actions of nitric oxide: confirmation using an inhibitor of the
soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996; 93: 1480–1485.
90. Schrammel A, Behrends S, Schmidt K et al. Characterization of
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of
nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996; 50: 1–5.
91. Feelisch M, Kotsonis P, Siebe J et al. The soluble guanylyl cyclase
inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective
heme protein inhibitor of nitric oxide synthase and other cytochrome
P-450 enzymes involved in nitric oxide donor bioactivation. Mol
Pharmacol 1999; 56: 243–253.
92. Zacharowski K, Berkels R, Olbrich A et al. The selective guanylate cyclase
inhibitor ODQ reduces multiple organ injury in rodent models of Gram-
positive and Gram-negative shock. Crit Care Med 2001; 29: 1599–1608.
93. Preiser JC, Sun Q, Hadj-Sadok D et al. Differential effects of a selective
inhibitor of soluble guanylyl cyclase on global and regional
hemodynamics during canine endotoxic shock. Shock 2003; 20:
465–468.
94. Waldron GJ, Cole WC. Activation of vascular smooth muscle K+ channels
by endothelium-derived relaxing factors. Clin Exp Pharmacol Physiol
1999; 26: 180–184.
95. Ahern GP, Klyachko VA, Jackson MB. cGMP and S-nitrosylation: two
routes for modulation of neuronal excitability by NO. Trends Neurosci
2002; 25: 510–517.
96. Tanaka Y, Koike K, Toro L. MaxiK channel roles in blood vessel
relaxations induced by endothelium-derived relaxing factors and their
molecular mechanisms. J Smooth Muscle Res 2004; 40: 125–153.
97. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J
Med 2001; 345: 588–595.
98. Buckley JF, Singer M, Clapp LH. Role of KATP channels in sepsis.
Cardiovasc Res 2006; 72: 220–230.
99. Bhatia M. Hydrogen sulfide as a vasodilator. IUBMB Life 2005; 57:
603–606.
100. Landry DW, Oliver JA. The ATP-sensitive K+ channel mediates
hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin
Invest 1992; 89: 2071–2074.
101. Wu CC, Thiemermann C, Vane JR. Glibenclamide-induced inhibition of
the expression of inducible nitric oxide synthase in cultured
564 Kidney International (2007) 72, 557–565
r e v i e w A Cauwels: Nitric oxide in shock
macrophages and in the anaesthetized rat. Br J Pharmacol 1995; 114:
1273–1281.
102. Vanelli G, Hussain SN, Aguggini G. Glibenclamide, a blocker of
ATP-sensitive potassium channels, reverses endotoxin-induced
hypotension in pig. Exp Physiol 1995; 80: 167–170.
103. Sorrentino R, d’Emmanuele di Villa Bianca R, Lippolis L et al. Involvement
of ATP-sensitive potassium channels in a model of a delayed vascular
hyporeactivity induced by lipopolysaccharide in rats. Br J Pharmacol
1999; 127: 1447–1453.
104. da Silva-Santos JE, Terluk MR, Assreuy J. Differential involvement of
guanylate cyclase and potassium channels in nitric oxide-induced
hyporesponsiveness to phenylephrine in endotoxemic rats. Shock 2002;
17: 70–76.
105. Warrillow S, Egi M, Bellomo R. Randomized, double-blind,
placebo-controlled crossover pilot study of a potassium channel
blocker in patients with septic shock. Crit Care Med 2006; 34: 980–985.
106. Oliver JA, Landry DW. Potassium channels and septic shock. Crit Care
Med 2006; 34: 1255–1257.
107. Robertson BE, Schubert R, Hescheler J et al. cGMP-dependent protein
kinase activates Ca-activated K channels in cerebral artery smooth
muscle cells. Am J Physiol 1993; 265: C299–C303.
108. Archer SL, Huang JM, Hampl V et al. Nitric oxide and cGMP cause
vasorelaxation by activation of a charybdotoxin-sensitive K channel by
cGMP-dependent protein kinase. Proc Natl Acad Sci USA 1994; 91:
7583–7587.
109. Ellis A, Triggle CR. Endothelium-derived reactive oxygen
species: their relationship to endothelium-dependent
hyperpolarization and vascular tone. Can J Physiol Pharmacol
2003; 81: 1013–1028.
110. Archer SL, Gragasin FS, Wu X et al. Endothelium-derived hyperpolarizing
factor in human internal mammary artery is 11,12-epoxyeicosatrienoic
acid and causes relaxation by activating smooth muscle BK(Ca)
channels. Circulation 2003; 107: 769–776.
111. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing
factor: where are we now? Arterioscler Thromb Vasc Biol 2006; 26:
1215–1225.
112. Clayton NP, LeDuc BW, Kelly LJ. Effect of potassium channel and
cytochrome P450 inhibition on transient hypotension and survival
during lipopolysaccharide-induced endotoxic shock in the rat.
Pharmacology 2005; 73: 113–120.
113. Pickkers P, Dorresteijn MJ, Bouw MP et al. In vivo evidence
for nitric oxide-mediated calcium-activated potassium-channel
activation during human endotoxemia. Circulation 2006; 114:
414–421.
114. Vergara C, Latorre R, Marrion NV et al. Calcium-activated potassium
channels. Curr Opin Neurobiol 1998; 8: 321–329.
115. Feletou M, Vanhoutte PM, Weston AH et al. EDHF and endothelial
potassiun channels: IKCa and SKCa. Br J Pharmacol 2003; 140: 225
(author reply 226).
116. Feletou M, Vanhoutte PM. EDHF: new therapeutic targets? Pharmacol
Res 2004; 49: 565–580.
117. Gluais P, Edwards G, Weston AH et al. Role of SK(Ca) and IK(Ca) in
endothelium-dependent hyperpolarizations of the guinea-pig isolated
carotid artery. Br J Pharmacol 2005; 144: 477–485.
118. Scotland RS, Madhani M, Chauhan S et al. Investigation of vascular
responses in endothelial nitric oxide synthase/cyclooxygenase-1
double-knockout mice: key role for endothelium-derived
hyperpolarizing factor in the regulation of blood pressure in vivo.
Circulation 2005; 111: 796–803.
119. Pastor CM, Suter PM. Evidence that humans produce less nitric oxide
than experimental animals in septic shock. Crit Care Med 1998; 26: 1135.
120. Zwaveling JH, Maring JK, Moshage H et al. Role of nitric oxide in
recombinant tumor necrosis factor-alpha-induced circulatory shock: a
study in patients treated for cancer with isolated limb perfusion. Crit
Care Med 1996; 24: 1806–1810.
121. Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as
an endogenous smooth muscle relaxant in synergy with nitric oxide.
Biochem Biophys Res Commun 1997; 237: 527–531.
122. Li L, Bhatia M, Zhu YZ et al. Hydrogen sulfide is a novel mediator of
lipopolysaccharide-induced inflammation in the mouse. FASEB J 2005;
19: 1196–1198.
123. Collin M, Anuar FB, Murch O et al. Inhibition of endogenous hydrogen
sulfide formation reduces the organ injury caused by endotoxemia.
Br J Pharmacol 2005; 146: 498–505.
124. Zhang H, Zhi L, Moore PK et al. Role of hydrogen sulfide in cecal ligation
and puncture-induced sepsis in the mouse. Am J Physiol Lung Cell Mol
Physiol 2006; 290: L1193–L1201.
125. Cuzzocrea S, Riley DP, Caputi AP et al. Antioxidant therapy: a new
pharmacological approach in shock, inflammation, and ischemia/
reperfusion injury. Pharmacol Rev 2001; 53: 135–159.
126. Thiemermann C. Membrane-permeable radical scavengers (tempol) for
shock, ischemia-reperfusion injury, and inflammation. Crit Care Med
2003; 31: S76–84.
127. Victor VM, Rocha M, De la Fuente M. Immune cells: free radicals and
antioxidants in sepsis. Int Immunopharmacol 2004; 4: 327–347.
128. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms.
J Allergy Clin Immunol 2002; 110: 341–348.
129. Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment
and diagnosis. Curr Opin Allergy Clin Immunol 2005; 5: 359–364.
130. Amir S, English AM. An inhibitor of nitric oxide production,
NG-nitro-L-arginine-methyl ester, improves survival in anaphylactic
shock. Eur J Pharmacol 1991; 203: 125–127.
131. Mitsuhata H, Saitoh J, Hasome N et al. Nitric oxide synthase inhibition is
detrimental to cardiac function and promotes bronchospasm in
anaphylaxis in rabbits. Shock 1995; 4: 143–148.
132. Bellou A, Lambert H, Gillois P et al. Constitutive nitric oxide synthase
inhibition combined with histamine and serotonin receptor blockade
improves the initial ovalbumin-induced arterial hypotension but
decreases the survival time in brown Norway rats anaphylactic shock.
Shock 2003; 19: 71–78.
133. Cauwels A, Janssen B, Buys E et al. Anaphylactic shock depends on PI3K
and eNOS-derived NO. J Clin Invest 2006; 116: 2244–2251.
Kidney International (2007) 72, 557–565 565
A Cauwels: Nitric oxide in shock r e v i e w
